{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:32:25Z","timestamp":1793431945681,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10549-019-05179-y","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T07:08:20Z","timestamp":1551337700000},"page":"525-530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Corneal features in trastuzumab emtansine treatment: not a rare occurrence"],"prefix":"10.1007","volume":"175","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6149-7968","authenticated-orcid":false,"given":"Els","family":"Deklerck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke O.","family":"Kreps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"key":"5179_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/phar.1687","volume":"36","author":"TV Jerjian","year":"2016","unstructured":"Jerjian TV, Glode AE, Thompson LA, O\u2019Bryant CL (2016) Antibody drug conjugates: a clinical pharmacy perspective on an emerging cancer therapy. Pharmacotherapy 36:99\u2013116","journal-title":"Pharmacotherapy"},{"key":"5179_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2016.02.008","volume":"40","author":"BE Goeij de","year":"2016","unstructured":"de Goeij BE, Lambert JM (2016) New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol 40:14\u201323","journal-title":"Curr Opin Immunol"},{"key":"5179_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","volume":"69","author":"JM Lambert","year":"2018","unstructured":"Lambert JM, Berkenblit A (2018) Antibody-drug conjugates for cancer treatment. Annu Rev Med 69:191\u2013207","journal-title":"Annu Rev Med"},{"key":"5179_CR4","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1097\/ICO.0000000000000868","volume":"35","author":"M Tsuda","year":"2016","unstructured":"Tsuda M, Takano Y, Shigeyasu C, Imoto S, Yamada M (2016) Abnormal corneal lesions induced by trastuzumab emtansine: an antibody-drug conjugate for breast cancer. Cornea 35:1378\u20131380","journal-title":"Cornea"},{"key":"5179_CR5","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1016\/j.clbc.2018.03.005","volume":"18","author":"EO Kreps","year":"2018","unstructured":"Kreps EO, Derveaux T, Denys H (2018) Corneal changes in trastuzumab emtansine treatment. Clin Breast Cancer 18:e427\u2013e429","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"5179_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/bjo.87.2.225","volume":"87","author":"I Jalbert","year":"2003","unstructured":"Jalbert I, Stapleton F, Papas E, Sweeney DF, Coroneo M (2003) In vivo confocal microscopy of the human cornea. Br J Ophthalmol 87(2):225\u2013236","journal-title":"Br J Ophthalmol"},{"key":"5179_CR7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","volume":"22","author":"AJ Bron","year":"2003","unstructured":"Bron AJ, Evans VE, Smith JA (2003) Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22:640\u2013650","journal-title":"Cornea"},{"key":"5179_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton JS, Miller PE, Mannis MJ, Murphy CJ (2015) Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 31:589\u2013604","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"5179_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.survophthal.2016.11.008","volume":"62","author":"MB Raizman","year":"2017","unstructured":"Raizman MB, Hamrah P, Holland EJ, Kim T, Mah FS, Rapuano CJ, Ulrich RG (2017) Drug-induced corneal epithelial changes. Surv Ophthalmol 62(3):286\u2013301. \n                    https:\/\/doi.org\/10.1016\/j.survophthal.2016.11.008","journal-title":"Surv Ophthalmol"},{"key":"5179_CR10","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.1158\/1078-0432.CCR-16-2862","volume":"23","author":"G Menderes","year":"2017","unstructured":"Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F et al (2017) SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2\/Neu expression. Clin Cancer Res 23:5836\u20135845","journal-title":"Clin Cancer Res"},{"key":"5179_CR11","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297.2017.2.test","volume":"19","author":"A Bardia","year":"2017","unstructured":"Bardia A, Mayer IA, Diamons JR, Moroose RL, Ikakoff et al (2017) Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol 19:2141\u20132148","journal-title":"J Clin Oncol"},{"key":"5179_CR12","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1167\/iovs.13-12943","volume":"55","author":"JL Peterson","year":"2003","unstructured":"Peterson JL, Phelps ED, Doll MA et al (2003) The role of endogenous epidermal growth factor receptor ligands in mediating corneal epithelial homeostasis. Invest Ophthalmol Vis Sci 55:2870\u20132880","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5179_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/sj.eye.6700451","volume":"17","author":"J Lochhead","year":"2003","unstructured":"Lochhead J, Salmon JF, Bron AJ (2003) Cytarabine-induced corneal toxicity. Eye 17:677\u2013678","journal-title":"Eye"},{"key":"5179_CR14","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1167\/iovs.04-0119","volume":"45","author":"KP Xu","year":"2004","unstructured":"Xu KP, Riggs A, Ding Y, Yu FS (2004) Role of ErbB2 in corneal epithelial wound healing. Invest Ophthalmol Vis Sci 45:4277\u20134283","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5179_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1186\/s12885-015-1969-3","volume":"15","author":"A Orlandi","year":"2015","unstructured":"Orlandi A, Fasciani R, Cassano A et al (2015) Trastuzumab-induced corneal ulceration: successful no-drug treatment of a \u201cblind\u201d side effect in a case report. BMC Cancer 15:973","journal-title":"BMC Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05179-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05179-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05179-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T19:09:13Z","timestamp":1582830553000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05179-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5179"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05179-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,28]]},"assertion":[{"value":"12 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare that the experiments comply with the current laws of the country in which they were performed (Belgium). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}